Evidence map›Paper›PMID 41057658›Full record

ArticleNature biotechnology2026

Folding-mediated secretion of pure bispecific antibodies.

Cholpon Tilegenova, Tun Liu, Qian Zhao, Mahati Are, Yu Zhao, Woo Suk Choi, Anusarka Bhaumik, Ruth Steele, Nicholas A Manieri, Bengi Turegun and 14 more

Erratum issuedAbstract read
In one paragraph

Article in Nature biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors.

Cholpon TilegenovaBiologics Discovery, Johnson & Johnson, Spring House, PA, USA.
Tun LiuBiologics Discovery, Johnson & Johnson, Spring House, PA, USA.
Qian ZhaoBiologics Discovery, Johnson & Johnson, Spring House, PA, USA.ORCID http://orcid.org/0000-0001-6555-4467
Mahati AreBiologics Discovery, Johnson & Johnson, Spring House, PA, USA.
Yu ZhaoBiologics Discovery, Johnson & Johnson, Spring House, PA, USA.
Woo Suk ChoiStructural & Protein Sciences, Johnson & Johnson, San Diego, CA, USA.
Anusarka BhaumikDiscovery Technology and Molecular Pharmacology, Johnson & Johnson, Spring House, PA, USA.
Ruth SteeleStructural & Protein Sciences, Johnson & Johnson, Spring House, PA, USA.
Nicholas A ManieriBiologics Discovery, Johnson & Johnson, Spring House, PA, USA.
Bengi TuregunBiologics Discovery, Johnson & Johnson, Spring House, PA, USA.
Alex NiTherapeutics Development and Supply, Johnson & Johnson, Malvern, PA, USA.
Rosa M F CardosoIn Silico Discovery, Johnson & Johnson, Spring House, PA, USA.
Paul ShafferStructural & Protein Sciences, Johnson & Johnson, Spring House, PA, USA.
Desmond ClarkBiologics Discovery, Johnson & Johnson, Spring House, PA, USA.
Robin ErnstBiologics Discovery, Johnson & Johnson, Spring House, PA, USA.
Wenyu LiPreclinical Sciences and Translational Safety, Johnson & Johnson, Spring House, PA, USA.
Tracy TaylorPreclinical Sciences and Translational Safety, Johnson & Johnson, Spring House, PA, USA.
Suresh Kumar SwaminathanPreclinical Sciences and Translational Safety, Johnson & Johnson, Spring House, PA, USA.
Bhargavi RamarajuBiologics Discovery, Johnson & Johnson, Spring House, PA, USA.
Kevin LiawBiologics Discovery, Johnson & Johnson, Spring House, PA, USA.
Steven A JacobsBiologics Discovery, Johnson & Johnson, Spring House, PA, USA.
Sujata SharmaStructural & Protein Sciences, Johnson & Johnson, Spring House, PA, USA.
Wan Cheung CheungBiologics Discovery, Johnson & Johnson, Spring House, PA, USA.
Adam ZwolakBiologics Discovery, Johnson & Johnson, Spring House, PA, USA. azwolak1@its.jnj.com.ORCID http://orcid.org/0000-0001-6861-9078

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bispecific antibodies (bsAbs) can enable therapeutic mechanisms, such as dual antigen targeting or receptor agonism, that are impossible using monoclonal antibodies. BsAbs with IgG-like format (bsIgG) are comprised of two unique heavy chains, each having a cognate light chain. Co-expression of these four unique polypeptides often leads to several mispaired species that are difficult to separate from the target bsIgG due to their similar biophysical properties. Here we describe a set of mutations called ProAla that exploit a the unfolded protein response pathway of cells. ProAla heavy chains are engineered with higher folding energy barriers such that only the cognate light and heavy chains can induce folding, chaperone release and secretion. The structures of the ProAla Fab and Fc regions are identical in structure to normal antibodies, enabling maintenance of half-life and function. Mispaired polypeptides fail to secrete from the cell due to enhanced interaction with the endoplasmic reticulum chaperone BiP, resulting in increased purity of secreted bsIgGs.

Indexed as

Antibodies, BispecificProtein FoldingAnimalsHumansProtein EngineeringUnfolded Protein ResponseAntibodies, Bispecific

Identifiers

PMID41057658
PMCPMC13558067

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.